Recessive dystrophic epidermolysis bullosa, also called RDEB, is one form of epidermolysis bullosa. Epidermolysis bullosa is a rare genetic condition that causes very fragile skin. With RDEB, even a ...

The FDA granted the first drug approval for dystrophic epidermolysis bullosa (DEB), a topical gene therapy that treats the blistering wounds it causes, the agency announced Friday. The herpes-simplex ...

Credit: Krystal Biotech. Vyjuvek is a topical HSV-1 vector-based gene therapy. The Food and Drug Administration (FDA) has approved Vyjuvek ™ (beremagene geperpavec-svdt) for the treatment of wounds in ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye. In 1999, I defined regenerative medicine as the collection of ...

The US Food and Drug Administration (FDA) has approved the first-ever topical gene therapy, which will be used to treat wounds in patients 6 months of age and older who have either recessive or ...

Beremagene geperpavec-svdt (B-VEC) entered the market in 2023 as the first approved corrective treatment for dystrophic epidermolysis bullosa (DEB), a rare genetic disease affecting the skin and nails ...

Rigosertib, a polo-like kinase 1 (PLK1) inhibitor, demonstrated antitumor efficacy in patients with recessive dystrophic epidermolysis bullosa (RDEB) and advanced squamous cell carcinoma (SCC), with ...

Please provide your email address to receive an email when new articles are posted on . Pregabalin targets the a2-delta auxiliary subunit of voltage-gated calcium channels. Patients with RDEB in this ...

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with recessive dystrophic epidermolysis bullosa. The approval is based on the pivotal ...

Please provide your email address to receive an email when new articles are posted on . Patients with dystrophic epidermolysis bullosa had positive phase 3 results with Vyjuvek treatment, Krystal ...

Dystrophic epidermolysis bullosa is a rare genetic blistering skin disease caused by mutations in COL7A1, which encodes type VII collagen (C7). Beremagene geperpavec (B-VEC) is a topical ...